Trials / Completed
CompletedNCT03429595
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
Randomized, Double-Blind, Vehicle Controlled, Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of Topical ATx201 GEL (2% and 4%) in Outpatients With Impetigo
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 210 (actual)
- Sponsor
- UNION therapeutics · Industry
- Sex
- All
- Age
- 9 Months – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study evaluating the safety, tolerability, systemic exposure, and activity of topical ATx201 GEL (2% and 4%) treatment for 1, 2, or 5 days in outpatients with primary nonbullous or bullous impetigo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATx201 | ATx201 GEL |
| OTHER | ATx201 GEL Vehicle | Vehicle |
Timeline
- Start date
- 2018-02-23
- Primary completion
- 2018-06-26
- Completion
- 2018-06-26
- First posted
- 2018-02-12
- Last updated
- 2018-07-31
Locations
16 sites across 1 country: South Africa
Source: ClinicalTrials.gov record NCT03429595. Inclusion in this directory is not an endorsement.